Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
FDA Orange Book
0
Canada
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-hydroxy-6-quinolinecarboxamide
2. 4-(3-chloro-4-((cyclopropylaminocarbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide
3. 4-(3-chloro-4-(n'-cyclopropylureido)phenoxy)-7-methoxyquinoline-6-carboxamide
4. E 7080
5. E-7080
6. E-7080 Mesylate
7. E7080
8. E7080 Mesylate
9. Er-203492-00
10. Lenvatinib Mesilate
11. Lenvatinib Mesylate
12. Lenvatinib Metabolite M2
13. Lenvatinib Methanesulfonate
14. Lenvima
15. N-(4-((6-carbamoyl-7-methoxyquinolin-4-yl)oxy)-2-chlorophenyl)-n'-cyclopropylurea Monomethanesulfonate
1. 417716-92-8
2. E7080
3. 4-(3-chloro-4-(3-cyclopropylureido)phenoxy)-7-methoxyquinoline-6-carboxamide
4. E7080 (lenvatinib)
5. Lenvatinib (e7080)
6. E-7080
7. E 7080
8. Er-203492-00
9. Lenvatinib Free Base
10. Unii-ee083865g2
11. 4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-7-methoxyquinoline-6-carboxamide
12. 4-[3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-methoxy-6-quinolinecarboxamide
13. 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxyquinoline-6-carboxamide
14. Chembl1289601
15. Chebi:85994
16. 417716-92-8 (free Base)
17. Ee083865g2
18. 4-(3-chloro-4-(n'-cyclopropylureido)phenoxy)-7-methoxyquinoline-6-carboxamide
19. 4-(3-chloro-4-((cyclopropylaminocarbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide
20. 4-[3-chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-6-quinolinecarboxamide
21. Lenvatinib [usan]
22. Lenvatinib [usan:inn]
23. Kisplyx
24. 4-(3-chloro-4-((cyclopropylcarbamoyl)amino)phenoxy)-7-methoxyquinoline-6-carboxamide
25. 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide
26. Lev
27. Lenvatinib; E7080
28. Lenvatinib [mi]
29. Lenvatinib Base- Bio-x
30. Lenvatinib [inn]
31. Lenvatinib (usan/inn)
32. Lenvatinib [who-dd]
33. Mls006011239
34. Schembl864638
35. Gtpl7426
36. Amy9240
37. Dtxsid50194605
38. Ex-a249
39. Bcpp000247
40. Hms3244a07
41. Hms3244a08
42. Hms3244b07
43. Hms3654a14
44. Bcp01799
45. Zinc3816292
46. Bdbm50331094
47. Mfcd16038644
48. Nsc755980
49. Nsc800781
50. S1164
51. Akos025401742
52. Bcp9000633
53. Ccg-264842
54. Cs-0109
55. Db09078
56. Nsc-755980
57. Nsc-800781
58. Sb16580
59. Ncgc00263198-01
60. Ncgc00263198-04
61. Ncgc00263198-07
62. Ac-25047
63. As-16203
64. Bl164616
65. Hy-10981
66. Smr004702999
67. Db-070219
68. Ft-0700727
69. Sw219259-1
70. D09919
71. 716c928
72. A825653
73. J-513372
74. Q6523413
75. Brd-k39974922-001-02-7
76. 4-[3-chloranyl-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxy-quinoline-6-carboxamide
77. N-(4-((6-carbamoyl-7-methoxyquinolin-4-yl)oxy)-2-chlorophenyl)-n'-cyclopropylurea
78. 4-[3-chloro-4-[[(cyclopropylamino)-oxomethyl]amino]phenoxy]-7-methoxy-6-quinolinecarboxamide
79. 6-quinolinecarboxamide, 4-(3-chloro-4- (((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-
80. 6-quinolinecarboxamide, 4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)- 7-methoxy-
81. 6-quinolinecarboxamide, 4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-
Molecular Weight | 426.9 g/mol |
---|---|
Molecular Formula | C21H19ClN4O4 |
XLogP3 | 2.8 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 5 |
Rotatable Bond Count | 6 |
Exact Mass | 426.1094828 g/mol |
Monoisotopic Mass | 426.1094828 g/mol |
Topological Polar Surface Area | 116 Ų |
Heavy Atom Count | 30 |
Formal Charge | 0 |
Complexity | 634 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Lenvatinib is indicated for the treatment of following conditions. - Treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer. - Treatment of advanced renal cell carcinoma (RCC) in combination with everolimus following one prior antiangiogenic therapy. - First-line treatment of unresectable hepatocellular carcinoma (HCC).
FDA Label
Lenvima is indicated as monotherapy for the treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hrthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine (RAI).
Lenvima is indicated as monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have received no prior systemic therapy.
Kisplyx is indicated for the treatment of adults with advanced renal cell carcinoma (RCC):
- in combination with pembrolizumab, as first-line treatment (see section 5. 1).
- in combination with everolimus, following one prior vascular endothelial growth factor (VEGF)-targeted therapy.
Treatment of follicular thyroid cancer , Treatment of osteosarcoma, Treatment of papillary thyroid cancer
Treatment of all conditions included in the category of malignant neoplasms except haematopoietic and lymphoid tissue neoplasms, papillary thyroid cancer , follicular thyroid cancer and osteosarcoma
Based on x-ray crystallography and kinetic interaction studies, lenvatinib binds to the adenosine 5'-triphosphate binding site of VEGFR2 and to a neighbouring region via a cyclopropane ring and thereby inhibits tyrosine kinase activity and associated signalling pathways.
Antineoplastic Agents
Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)
Protein Kinase Inhibitors
Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)
L01XE
L01XE29
L01XE29
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
L - Antineoplastic and immunomodulating agents
L01 - Antineoplastic agents
L01E - Protein kinase inhibitors
L01EX - Other protein kinase inhibitors
L01EX08 - Lenvatinib
Absorption
Time to peak plasma concentration occurred from 1 to 4 hours postdose. Administration with food did not affect the extent of absorption, but decreased the rate of absorption and delayed the median Tmax from 2 hours to 4 hours.
Route of Elimination
Following administration of a radiolabeled dose, approximately 64% and 25% of the radiolabel were eliminated in the feces and urine, respectively.
Lenvatinib is metabolized by CYP3A and aldehyde oxidase.
The terminal elimination halflife of lenvatinib is approximately 28 hours.
Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; the platelet derived growth factor receptor alpha (PDGFR), KIT, and RET.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 33195
Submission : 2018-09-29
Status : Active
Type : II
Date of Issue : 2022-09-02
Valid Till : 2025-05-05
Written Confirmation Number : WC-0349
Address of the Firm : MIs. MSN Laboratories Private Limited, Unit-II, sv. No, 50, Kardanur (Village), ...
Date of Issue : 2020-09-30
Valid Till : 2022-05-05
Written Confirmation Number : WC-0349A9
Address of the Firm : Unit-||, Sy. No. 50, Kardanur Village, Patti/Post Patancheru Mandal,Medak Distri...
NDC Package Code : 68554-0160
Start Marketing Date : 2015-02-13
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 54893-0080
Start Marketing Date : 2018-09-29
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Faran Shimi: Leading producer of high-quality APIs & alkaloid opiates, serving major pharmaceutical companies across the Middle East.
About the Company : Faran Shimi Pharmaceutical Company, established in 2001 and affiliated with Golrang Pharmaceutical Investment Co, manufactures high-quality Active Pharmaceutical Ingredients (APIs)...
About the Company : Cipla is a global pharmaceutical company whose goal is ensuring no patient shall be denied access to high quality & affordable medicine and support. Mission: Cipla’s mission i...
About the Company : Fujian South Pharmaceutical Co., Ltd. (Southern Pharmaceutical) was established in September 2001 and is located in Mingxi County, Fujian Province. After 16 years of development, ...
About the Company : Established in 2011 and situated in Hangzhou, Zhejiang, China, Hangzhou Longshine Bio-Tech CO., Ltd is dedicated to providing services for pharmaceutical and chemical products, cat...
About the Company : Haoyuan Chemexpress Co., Ltd., located in Shanghai Zhangjiang Biomedical Base, is a high-tech company specializing in customized chemical synthesis and R&D of pharmaceutical interm...
About the Company : Shandong Hao Hong Biotechnology Co., Ltd. is located in Provincial Chemical Industrial Park of Liaocheng city, Shandong province, which is a beautiful water city. And recently anot...
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Lenvatinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Lenvatinib, including repackagers and relabelers. The FDA regulates Lenvatinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Lenvatinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Lenvatinib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Lenvatinib supplier is an individual or a company that provides Lenvatinib active pharmaceutical ingredient (API) or Lenvatinib finished formulations upon request. The Lenvatinib suppliers may include Lenvatinib API manufacturers, exporters, distributors and traders.
click here to find a list of Lenvatinib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Lenvatinib DMF (Drug Master File) is a document detailing the whole manufacturing process of Lenvatinib active pharmaceutical ingredient (API) in detail. Different forms of Lenvatinib DMFs exist exist since differing nations have different regulations, such as Lenvatinib USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Lenvatinib DMF submitted to regulatory agencies in the US is known as a USDMF. Lenvatinib USDMF includes data on Lenvatinib's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Lenvatinib USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Lenvatinib suppliers with USDMF on PharmaCompass.
A Lenvatinib written confirmation (Lenvatinib WC) is an official document issued by a regulatory agency to a Lenvatinib manufacturer, verifying that the manufacturing facility of a Lenvatinib active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Lenvatinib APIs or Lenvatinib finished pharmaceutical products to another nation, regulatory agencies frequently require a Lenvatinib WC (written confirmation) as part of the regulatory process.
click here to find a list of Lenvatinib suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Lenvatinib as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Lenvatinib API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Lenvatinib as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Lenvatinib and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Lenvatinib NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Lenvatinib suppliers with NDC on PharmaCompass.
Lenvatinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Lenvatinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Lenvatinib GMP manufacturer or Lenvatinib GMP API supplier for your needs.
A Lenvatinib CoA (Certificate of Analysis) is a formal document that attests to Lenvatinib's compliance with Lenvatinib specifications and serves as a tool for batch-level quality control.
Lenvatinib CoA mostly includes findings from lab analyses of a specific batch. For each Lenvatinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Lenvatinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Lenvatinib EP), Lenvatinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Lenvatinib USP).
LOOKING FOR A SUPPLIER?